PR Newswire
NEW YORK , Aug. 24, 2021 /PRNewswire/ -- Vaccines are known for the stringent cold chain storage requirements necessary to maintain their integrity. In the U.S., maintaining refrigerated or frozen conditions is a simple logistical hurdle. In developing nations, however, vaccine storage is a considerable challenge for the nearly three billion people who live in regions lacking temperature-controlled storage . As new vaccines are engineered, the development of thermally stable vaccines has lagged.
Late-stage biopharmaceutical company, Soligenix (Nasdaq:SNGX), has shared preclinical data demonstrating that its thermostable vaccine platform may be an important contributor to addressing the next potential pandemic and future health emergencies.
Key findings include:
- Demonstrated successful formulation and heat stabilization of filovirus vaccine platform published in Vaccine
- Potent efficacy data in monovalent (single antigen) and bivalent (two antigens) formulations demonstrated in non-human primates (NHPs) published in Frontiers in Immunology
- Efficacy of thermostabilized vaccine formulations in NHPs in single-vial presentation
- Demonstrated feasibility of rapid and efficient manufacturing.
Preparing for future health emergencies
In July, concerns over the next potential pandemic saw Dr. Anthony Fauci push a multi-billion dollar plan to develop "prototype" vaccines against different virus threats including Sudan ebolavirus .
Soligenix collaborators at the University of Hawai'i at M?noa (UHM) are working with thermostabilized vaccine candidates protecting against three life-threatening filoviruses , including Sudan ebolavirus. Their formulations have demonstrated potent immune responses in NHPs . Filoviruses are endemic in areas of the world with uncertain power supply, making a thermostable vaccine particularly valuable to address emerging outbreaks.
Translating into broadly applicable platform
Soligenix's filovirus program has demonstrated its compatibility with thermostabilization, and the identification of key stability indicating assays - both hallmarks of a broadly applicable vaccine platform. Using this platform, the company will accelerate its joint COVID-19 vaccine effort, with the development of CiVax™, a heat stable COVID-19 vaccine candidate.
Sufficient capital to achieve pipeline goals
Soligenix is in a comfortable position to pursue its strategic goals. As of June 30 2021, the Company reported a cash position of approximately $29 million , providing sufficient capital to achieve multiple inflection points as it advances its rare disease pipeline and evaluates partnership and M&A opportunities into 2022.
Disclaimer
This communication was produced by PCG Digital Holdings, LLC, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its client's securities. See www.pcgadvisory.com/disclosures .
PCG Digital
info@pcgadvisory.com
646-863-6341
SOURCE PCG Digital